Search

everythinglearnresearchcommunity

for

Search:↓

A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.

The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.

Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.

A user experiencing significant hair loss started using Dutasteride, a drug typically used for prostate issues, and noticed a positive change in hair thickness and volume after 5 months. Other users in the conversation also shared their experiences and observations with Dutasteride, with one mentioning additional use of oral Minoxidil.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.

A user discusses their experience with hair loss, noting they don't notice shedding despite using finasteride, minoxidil, and tretinoin. Others share similar experiences, suggesting that shedding varies and may not occur for everyone using these treatments.

A user's 3-month experience with pyrilutamide to reduce hair shedding, and how it may not be strong enough to stop the thinning of their hairline. Other users mentioned the effectiveness of minoxidil and finasteride for treating hair loss.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

A user is experiencing significant hair shedding after starting a treatment regimen of 1mg oral finasteride, 3mg oral minoxidil, 2.5mg biotin, and vitamins. Despite the shedding, they remain optimistic and plan to continue the treatment for a year before making any conclusions.

A user reported losing hair after 7 months of using oral minoxidil, finasteride, and dutasteride, but others reassured that this is likely just a shedding phase where old hairs fall out to make way for new growth. Some users experience sheds every 7-8 months and suggest staying consistent with treatment.

Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

A user shared progress pictures showing hair improvement after using oral finasteride and topical minoxidil for two and a half months. They are considering a hair transplant but are advised to wait for full results from the treatments.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

Maintaining scalp hair and minimizing shedding, treatments used such as Procapil, supplements, topical caffeine, topical estrogen, and scalp massage; suggestions for anagen extenders or pharmaceuticals to help with a short anagen phase.